Methylprednisolone or budesonide (DrugBank: Methylprednisolone, Budesonide)
9 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
66 | IgA nephropathy | 0 |
93 | Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)] | 0 |
94 | Primary sclerosing cholangitis | 0 |
95 | Autoimmune hepatitis | 0 |
96 | Crohn disease | 1 |
97 | Ulcerative colitis | 0 |
98 | Eosinophilic gastrointestinal disease | 0 |
228 | Bronchiolitis obliterans | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00554710 (ClinicalTrials.gov) | May 2001 | 6/11/2007 | Top Down Versus Step Up Strategies in Crohn's Disease | The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux | Crohn's Disease | Drug: infliximab+azathioprine;Drug: methylprednisolone or budesonide | Belgian IBD Research Group | Centocor BV;Schering-Plough | Completed | 16 Years | 75 Years | Both | 129 | Phase 4 | Belgium |